Australasian College of Dermatologists 2017 E-Posters

Secukinumab demonstrates sustained high efficacy and a tolerable safety profile in moderate-to-severe psoriasis patients through 4 years of treatment
Mr Eric Mate
Secukinumab is efficacious in clearing moderate-to-severe scalp psoriasis: 12 week results of a randomised phase IIIb study
Mr Eric Mate